Business
Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)
– SER-155 is designed to reduce the incidence of infection, mortality and GvHD in adults undergoing hematopoietic stem cell transplantation (HSCT) – – Seres
About this update from Seres Therapeutics, Inc.
[{"type":"text","content":"\n– SER-155 is designed to reduce the incidence of infection, mortality and GvHD in adults undergoing hematopoietic stem cell transplantation (HSCT) –\n\n– Seres is collaborating with Memorial Sloan Kettering Cancer Center and The University of Chicago for the study –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSeres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that the first patient has been enrolled in the SER-155 Phase 1b study. SER-155 is an investigational, oral, cultivated microbiome therapeutic. The consortia is a rationally-designed selection of bacteria optimized to enhance desired pharmacological properties to reduce the incidence of gastrointestinal bacterial infections, bacteremia and graft-versus-host disease (GvHD) in immunocompromised patients, including patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Prior published studies by Memorial Sloan Kettering Cancer Center collaborators indicate that HSCT patients with a disrupted, low diversity microbiome are at substantially increased risk for bacterial infections, including antibiotic resistant infection, and poor clinical outcomes.\n\nThe trial (NCT04995653) is designed to evaluate the efficacy, safety and microbiome alterations associated with SER-155 in adult subjects who are undergoing HSCT. The primary endpoints of the study are to assess safety as well as engraftment, which is characterized by the growth of drug bacteria in the gastrointestinal tract. SER-155 strains are measured before and after treatment courses through Day 100. The trial will enroll approximately 70 patients in both an open-label and a randomized, double-blind, placebo-controlled, multicenter study that will evaluate safety and tolerability before and after HSCT.\n\n“Antibiotic-resistant bacterial infections are a top priority to address globally, especially given the significant implications for HSCT and other cancer and immunocompromised patients,” said Lisa von Moltke, M.D., Chief Medical Officer at Seres. “SER-155 is designed to reduce the risk of infection and GvHD, so we’re eager to enroll patients and advance our investigation of this promising therapeutic candidate.”\n\nEric Shaff, Chief Executive Office at Seres, added, “Building on the compelling results we have obtained from our lead SER-109 program, we wil...